What is BriaCell Therapeutics Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BriaCell Therapeutics's annualizedGross Profit for the quarter that ended in Jan. 2025 was $0.00 Mil.
BriaCell Therapeutics's average Total Assets over the quarter that ended in Jan. 2025 was $9.89 Mil. Therefore, BriaCell Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2025 was 0.00%.
BriaCell Therapeutics Gross-Profit-to-Asset % Historical Data
The historical data trend for BriaCell Therapeutics's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BriaCell Therapeutics's Gross-Profit-to-Asset %
For the Biotechnology subindustry, BriaCell Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BriaCell Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where BriaCell Therapeutics's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Jan. 2025) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
BriaCell Therapeutics Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of BriaCell Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCTX has been successfully added to your 